For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Attruby represents a significant advancement . These groundbreaking therapies stabilize the transthyretin protein, slowing its damaging build-up and reducing the severity